Status In progress
Process STA
ID number 995

Provisional Schedule

Committee meeting: 2 23 November 2017
Expected publication 28 February 2018

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors Bristol-Myers Squibb (nivolumab)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Action Bladder Cancer UK
  Fight Bladder Cancer
Professional groups Association of Cancer Physicians
  British Uro-Oncology Group
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord Healthcare (carboplatin, docetaxel, paclitaxel) (CAU not returned, not participating)
  Actavis UK (docetaxel, paclitaxel) (CAU not returned, not participating)
  Dr Reddy's Laboratories (docetaxel) (CAU not returned, not participating)
  Hospira (carboplatin, docetaxel, paclitaxel) (CAU not returned, not participating)
  Medac (docetaxel, paclitaxel) (CAU not returned, not participating)
  Merck Sharp & Dohme (pembrolizumab)
  Peckforton Pharmaceuticals (paclitaxel) (CAU not returned, not participating)
  Roche (atezolizumab)
  Sanofi (docetaxel) (CAU not returned, not participating)
  Seacross Pharmaceuticals (docetaxel) (CAU not returned, not participating)
  Sun Pharmaceuticals UK (carboplatin) (CAU not returned, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
20 October 2017 - 09 November 2017 Appraisal consultation: 1
27 September 2017 Committee meeting: 1
26 April 2017 Invitation to participate
26 April 2017 In progress, Invitation to participate
01 March 2017 Referral
07 February 2017 - 28 February 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance